SEMPRUS BioSciences Closes $18 Million Series B Round

Published: Dec 14, 2010

Mass High Tech -- Cambridge-based biomedical company focused on antibacterial coatings Semprus BioSciences Inc. has closed on an $18 million Series B financing round, led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners. According to Semprus officials, 5AM Ventures and Pangaea Ventures, both of whom invested in the company’s Series A financing, participated in the Series B round.

Back to news